85 Kodiak Sciences Inc. Consolidated Balance Sheets (in thousands, except share and per share amounts) December 31, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents.............................................................................................. $ 168,074 $ 285,507 Prepaid expenses and other current assets........................................................................ 3,862 3,802 Total current assets.................................................................................................... 171,936 289,309 Restricted cash.................................................................................................................. 6,184 6,324 Property and equipment, net............................................................................................... 102,222 120,482 Operating lease right-of-use asset ....................................................................................... 46,508 54,541 Other assets ...................................................................................................................... 8,728 8,716 Total assets............................................................................................................... $ 335,578 $ 479,372 Liabilities and stockholders’ equity Current liabilities: Accounts payable.......................................................................................................... $ 3,915 $ 13,608 Accrued and other current liabilities................................................................................ 11,030 18,351 Operating lease liability................................................................................................. 10,628 9,770 Total current liabilities............................................................................................... 25,573 41,729 Operating lease liability, net of current portion..................................................................... 59,717 71,862 Liability related to sale of future royalties............................................................................ 100,000 100,000 Total liabilities.......................................................................................................... 185,290 213,591 Commitments and contingencies (Note 8) Stockholders’ equity: Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively ................................................................................. — — Common stock, $0.0001 par value, 490,000,000 shares authorized at December 31, 2024 and December 31, 2023; 52,726,916 and 52,508,602 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively ................................................................................. 5 5 Additional paid-in capital................................................................................................... 1,479,021 1,418,307 Accumulated deficit .......................................................................................................... (1,328,738) (1,152,531) Total stockholders’ equity.......................................................................................... 150,288 265,781 Total liabilities and stockholders’ equity ..................................................................... $ 335,578 $ 479,372 The accompanying notes are an integral part of these consolidated financial statements.